title: Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease.
abstract: OBJECTIVE
  T-cell-rich B-cell lymphoma is a rare variant of diffuse large B-cell lymphoma. It shows morphologic, phenotypic and molecular similarities to lymphocyte predominant Hodgkin's disease, and in consequence the two diseases may sometimes be difficult to distinguish. In this paper, we have evaluated the usefulness of the pan-leukocyte marker LSP1 and the transcription factor PU.1 for resolving such diagnostic problems.
  
  
  METHODS
  Immunohistochemical techniques were used to investigate the expression of LSP1 and PU.1 in 34 tumors, comprising typical examples of T-cell-rich B-cell lymphoma (15 cases), lymphocyte-predominant Hodgkin's disease (13 cases), and lymphocyte-rich classical Hodgkin's disease (6 cases).
  
  
  RESULTS
  The neoplastic cells of T-cell-rich B-cell lymphoma were LSP1-positive and PU.1-negative, whereas the lymphocytic and/or histiocytic (L&H) cells of lymphocyte-predominant Hodgkin's disease were mostly LSP1-negative, with variable PU.1 expression. The two markers did not discriminate between T-cell-rich B-cell lymphoma and lymphocyte-rich classical Hodgkin's disease, whilst they concurred to the distinction between lymphocyte-predominant and lymphocyte-rich classical Hodgkin's disease by integrating the already available tools.
  
  
  CONCLUSIONS
  Antibodies to LSP1 and PU.1 may represent useful reagents for the differential diagnosis between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease.
authors.affiliation: Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
authors.forename: Teresa
authors.initials: T
authors.lastname: Marafioti
authors.forename: Cristina
authors.initials: C
authors.lastname: Mancini
authors.forename: Stefano
authors.initials: S
authors.lastname: Ascani
authors.forename: Elena
authors.initials: E
authors.lastname: Sabattini
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Michela
authors.initials: M
authors.lastname: Pozzobon
authors.forename: Karen
authors.initials: K
authors.lastname: Pulford
authors.forename: Brunangelo
authors.initials: B
authors.lastname: Falini
authors.forename: Elaine S
authors.initials: ES
authors.lastname: Jaffe
authors.forename: Hans-Konrad
authors.initials: HK
authors.lastname: Müller-Hermelink
authors.forename: David Y
authors.initials: DY
authors.lastname: Mason
authors.forename: Stefano A
authors.initials: SA
authors.lastname: Pileri
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood; D003937:Diagnosis, Differential; D005260:Female; D006689:Hodgkin Disease / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D027381:Liver-Specific Organic Anion Transporter 1 / Q000097:blood* / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D008285:Major Histocompatibility Complex; D008297:Male; D009367:Neoplasm Staging; D011518:Proto-Oncogene Proteins / Q000097:blood* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D015534:Trans-Activators / Q000097:blood* / Q000276:immunology; D000099232:Proto-Oncogene Protein Spi-1
chemical_list: D000906:Antibodies; D027381:Liver-Specific Organic Anion Transporter 1; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D000099232:Proto-Oncogene Protein Spi-1